• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Nautilus Biotechnology Inc.

    4/28/26 4:10:06 PM ET
    $NAUT
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $NAUT alert in real time by email
    DEFA14A 1 nautilusdefa14anotice2026a.htm DEFA14A Nautilus DEFA14A notice 2026

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    _____________________________________________________________________
    SCHEDULE 14A
    Proxy Statement Pursuant to Section 14(a) of the
    Securities Exchange Act of 1934
    _____________________________________________________________________
    Filed by the Registrant x
    Filed by a Party other than the Registrant ¨

    Check the appropriate box:
    ¨Preliminary Proxy Statement
    ¨Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
    ¨Definitive Proxy Statement
    xDefinitive Additional Materials
    ¨Soliciting Material under §240.14a-12
    NAUTILUS BIOTECHNOLOGY, INC.
    (Name of Registrant as Specified In Its Charter)
    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)
    Payment of Filing Fee (Check all boxes that apply):
    xNo fee required.
    ¨Fee paid previously with preliminary materials.
    ¨Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.



     
    Your Vote Counts! Smartphone users Point your camera here and vote without entering a control number For complete information and to vote, visit www.ProxyVote.com Control # V92016-P46878 *Please check the meeting materials for any special requirements for meeting attendance. NAUTILUS BIOTECHNOLOGY, INC. 2026 Annual Meeting Vote by June 16, 2026 11:59 PM ET NAUTILUS BIOTECHNOLOGY, INC. 2701 EASTLAKE AVE EAST SEATTLE, WA 98102-4188 You invested in NAUTILUS BIOTECHNOLOGY, INC. and it’s time to vote! You have the right to vote on proposals being presented at the Annual Meeting. This is an important notice regarding the availability of proxy materials for the stockholder meeting to be held on June 17, 2026. Vote Virtually at the Meeting* June 17, 2026 10:00 AM PDT Virtually at: www.virtualshareholdermeeting.com/NAUT2026 Get informed before you vote View the Notice and Proxy Statement and Annual Report on Form 10-K online OR you can receive a free paper or email copy of the material(s) by requesting prior to June 3, 2026. If you would like to request a copy of the material(s) for this and/or future stockholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1-800-579-1639 or (3) send an email to sendmaterial@proxyvote.com. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy.


     
    Vote at www.ProxyVote.com Prefer to receive an email instead? While voting on www.ProxyVote.com, be sure to click “Delivery Settings”. Voting Items Board Recommends V92017-P46878 THIS IS NOT A VOTABLE BALLOT This is an overview of the proposals being presented at the upcoming stockholder meeting. Please follow the instructions on the reverse side to vote these important matters. 1. Election of Class II Directors For Nominees: 01) Parag Mallick 02) Farzad Nazem 2. Ratification of the appointment of PricewaterhouseCoopers, LLP as our independent registered public accounting firm for the year ended December 31, 2026. For 3. Approval on an advisory basis of the compensation of our named executive officers for the fiscal year ended December 31, 2025 (the “Say on Pay Vote”). For 4. Approval on an advisory basis of the frequency of future Say on Pay Votes. 1 Year NOTE: In their discretion, the proxyholders will vote on such other business as may properly come before the meeting or any adjournment or postponement thereof.


     
     
    Get the next $NAUT alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NAUT

    DatePrice TargetRatingAnalyst
    12/5/2024$1.75Neutral → Sell
    Goldman
    6/27/2024$6.00Buy
    Guggenheim
    6/3/2024$3.00Hold
    Jefferies
    1/6/2022$8.00Equal-Weight
    Morgan Stanley
    11/2/2021Outperform
    Cowen & Co.
    8/4/2021$10.00Neutral
    Goldman Sachs
    7/13/2021$13.00Buy
    Jefferies
    More analyst ratings

    $NAUT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Nautilus Biotechnology Reports First Quarter 2026 Financial Results

    SEATTLE, April 28, 2026 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ:NAUT), a company pioneering a single-molecule proteome analysis platform, today reported financial results for the first quarter ended March 31, 2026. First Quarter 2026 Business Highlights Initiated our Iterative Mapping Early Access Program, enabling broader access to our validated Tau proteoform assay, with Baylor College of Medicine as our first customer in a National Institutes of Health-funded cancer study.Advanced processing and analysis of Tau proteoform samples from collaborators, supporting platform validation and future scientific publications.Appointed Amber Faust as Vice President of Global Sale

    4/28/26 8:00:00 AM ET
    $NAUT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Nautilus Biotechnology to Announce First Quarter 2026 Financial Results on April 28, 2026

    SEATTLE, April 09, 2026 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ:NAUT, or "Nautilus")), a company pioneering a single-molecule protein analysis platform, today announced it will report financial results for the first quarter 2026 before market open on Tuesday, April 28, 2026. The company's management will webcast a corresponding conference call beginning at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time to discuss its results, business developments, and outlook. Live audio of the webcast will be available on the "Investors" section of the company website at: www.nautilus.bio. About Nautilus Biotechnology, Inc.With its corporate headquarters in Seattle, Washington and its

    4/9/26 8:00:00 AM ET
    $NAUT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Nautilus Biotechnology to Participate in the Investor Summit Group Virtual Conference

    SEATTLE, March 24, 2026 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ:NAUT, or "Nautilus")), a company pioneering a single-molecule protein analysis platform, today announced the company will be participating in the Investor Summit Group Virtual Conference. Nautilus' management is scheduled to present on Wednesday, March 25, 2026, at 10:00 a.m. Pacific Time / 1:00 p.m. Eastern Time. Interested parties may access live and archived webcasts of the presentations on the "Investors" section of the company website at: www.nautilus.bio. About Nautilus Biotechnology, Inc.With its corporate headquarters in Seattle, Washington and its research and development headquarters in San Carlos,

    3/24/26 8:00:00 AM ET
    $NAUT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $NAUT
    SEC Filings

    View All

    SEC Form DEFA14A filed by Nautilus Biotechnology Inc.

    DEFA14A - Nautilus Biotechnology, Inc. (0001808805) (Filer)

    4/28/26 4:10:06 PM ET
    $NAUT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form DEF 14A filed by Nautilus Biotechnology Inc.

    DEF 14A - Nautilus Biotechnology, Inc. (0001808805) (Filer)

    4/28/26 4:09:24 PM ET
    $NAUT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form 10-Q filed by Nautilus Biotechnology Inc.

    10-Q - Nautilus Biotechnology, Inc. (0001808805) (Filer)

    4/28/26 4:07:50 PM ET
    $NAUT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $NAUT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CEO, President, and Secretary Patel Sujal M bought $65,238 worth of shares (25,000 units at $2.61), increasing direct ownership by 0.24% to 10,366,721 units (SEC Form 4)

    4 - Nautilus Biotechnology, Inc. (0001808805) (Issuer)

    3/4/26 6:37:20 PM ET
    $NAUT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Chief Marketing Officer Suzuki Kentaro bought $5,960 worth of shares (4,000 units at $1.49) (SEC Form 4)

    4 - Nautilus Biotechnology, Inc. (0001808805) (Issuer)

    11/10/25 9:29:14 PM ET
    $NAUT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    CEO, President, and Secretary Patel Sujal M bought $135,575 worth of shares (200,000 units at $0.68), increasing direct ownership by 2% to 10,341,721 units (SEC Form 4)

    4 - Nautilus Biotechnology, Inc. (0001808805) (Issuer)

    9/9/25 4:42:25 PM ET
    $NAUT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $NAUT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CEO, President, and Secretary Patel Sujal M bought $65,238 worth of shares (25,000 units at $2.61), increasing direct ownership by 0.24% to 10,366,721 units (SEC Form 4)

    4 - Nautilus Biotechnology, Inc. (0001808805) (Issuer)

    3/4/26 6:37:20 PM ET
    $NAUT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form 4 filed by CFO and Treasurer Mowry Anna

    4 - Nautilus Biotechnology, Inc. (0001808805) (Issuer)

    3/4/26 5:31:36 PM ET
    $NAUT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form 4 filed by Chief Scientist Mallick Parag

    4 - Nautilus Biotechnology, Inc. (0001808805) (Issuer)

    3/4/26 5:31:31 PM ET
    $NAUT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $NAUT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Nautilus Biotechnology downgraded by Goldman with a new price target

    Goldman downgraded Nautilus Biotechnology from Neutral to Sell and set a new price target of $1.75

    12/5/24 7:46:35 AM ET
    $NAUT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Guggenheim initiated coverage on Nautilus Biotechnology with a new price target

    Guggenheim initiated coverage of Nautilus Biotechnology with a rating of Buy and set a new price target of $6.00

    6/27/24 7:49:37 AM ET
    $NAUT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Jefferies resumed coverage on Nautilus Biotechnology with a new price target

    Jefferies resumed coverage of Nautilus Biotechnology with a rating of Hold and set a new price target of $3.00

    6/3/24 8:53:10 AM ET
    $NAUT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $NAUT
    Financials

    Live finance-specific insights

    View All

    Nautilus Biotechnology Reports First Quarter 2026 Financial Results

    SEATTLE, April 28, 2026 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ:NAUT), a company pioneering a single-molecule proteome analysis platform, today reported financial results for the first quarter ended March 31, 2026. First Quarter 2026 Business Highlights Initiated our Iterative Mapping Early Access Program, enabling broader access to our validated Tau proteoform assay, with Baylor College of Medicine as our first customer in a National Institutes of Health-funded cancer study.Advanced processing and analysis of Tau proteoform samples from collaborators, supporting platform validation and future scientific publications.Appointed Amber Faust as Vice President of Global Sale

    4/28/26 8:00:00 AM ET
    $NAUT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Nautilus Biotechnology to Announce First Quarter 2026 Financial Results on April 28, 2026

    SEATTLE, April 09, 2026 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ:NAUT, or "Nautilus")), a company pioneering a single-molecule protein analysis platform, today announced it will report financial results for the first quarter 2026 before market open on Tuesday, April 28, 2026. The company's management will webcast a corresponding conference call beginning at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time to discuss its results, business developments, and outlook. Live audio of the webcast will be available on the "Investors" section of the company website at: www.nautilus.bio. About Nautilus Biotechnology, Inc.With its corporate headquarters in Seattle, Washington and its

    4/9/26 8:00:00 AM ET
    $NAUT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Nautilus Biotechnology Reports Fourth Quarter and Fiscal Year 2025 Financial Results

    SEATTLE, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ:NAUT), a company pioneering a single-molecule proteome analysis platform, today reported financial results for the fourth quarter and fiscal year ended December 31, 2025. Fourth Quarter 2025 and Fiscal Year 2025 Business Highlights Continued progress was made in processing and analyzing Tau proteoform samples from collaborators to support platform validation and expanding scientific publications. Externally generated Tau data measured on the Nautilus Voyager™ platform was presented at the World HUPO conference, and collaborators are advancing results toward submission for publication.Further progress was made

    2/26/26 8:00:00 AM ET
    $NAUT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $NAUT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Nautilus Biotechnolgy Inc.

    SC 13D/A - Nautilus Biotechnology, Inc. (0001808805) (Subject)

    11/14/24 4:31:50 PM ET
    $NAUT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form SC 13D/A filed by Nautilus Biotechnolgy Inc. (Amendment)

    SC 13D/A - Nautilus Biotechnology, Inc. (0001808805) (Subject)

    11/16/23 9:18:26 PM ET
    $NAUT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form SC 13D/A filed by Nautilus Biotechnolgy Inc. (Amendment)

    SC 13D/A - Nautilus Biotechnology, Inc. (0001808805) (Subject)

    3/1/23 3:30:45 PM ET
    $NAUT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $NAUT
    Leadership Updates

    Live Leadership Updates

    View All

    Nautilus Biotechnology Appoints Proteomics Commercial Leader Amber Faust as Vice President of Sales

    SEATTLE, March 02, 2026 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ:NAUT), a company pioneering single-molecule proteome analysis, today announced the appointment of Amber Faust as Vice President of Sales. Ms. Faust joins Nautilus following the public debut of the Nautilus Voyager™ Platform, designed to deliver and scale Iterative Mapping, a method that enables single-molecule analysis of proteins and proteoforms across the proteome. Ms. Faust brings nearly two decades of commercial leadership experience in life sciences, with a focus on advancing adoption of emerging proteomics technologies across pharmaceutical, biotechnology, academic, clinical, and government sectors. S

    3/2/26 8:00:00 AM ET
    $NAUT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Nautilus Biotechnology Appoints Mass Spectrometry Leader Ken Suzuki as Chief Marketing Officer

    SEATTLE, Sept. 17, 2024 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ:NAUT, or "Nautilus"))), a company pioneering a single-molecule protein analysis platform for comprehensively quantifying the proteome, today announced the appointment of Kentaro (Ken) Suzuki as Chief Marketing Officer. Mr. Suzuki joins Nautilus after 25 years in product and marketing leadership roles at Agilent Technologies, most recently serving as Vice President and General Manager of Agilent's Mass Spectrometry division. He has held numerous leadership positions at Agilent, including in the Strategic Program Office and Certified Pre-Owned Instruments, CrossLab Services and Support, and Spectroscopy. "Ke

    9/17/24 8:00:00 AM ET
    $NAUT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Nautilus Biotechnology Appoints Martin Huber, Ph.D., as Vice President of Biochemistry and Flow Cell Development

    SEATTLE, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ:NAUT, or "Nautilus"))), a company pioneering a single-molecule protein analysis platform for quantifying the proteome, today announced the expansion of its research and development senior leadership team with the appointment of Martin Huber, Ph.D., as Vice President of Biochemistry and Flow Cell Development. Dr. Huber brings to Nautilus over 20 years of experience in biotechnology start-ups both in Europe and the US, most recently as founder, CTO and, ultimately, CEO of Quantapore, a company devoted to pioneering massively parallel, direct, single-molecule DNA and protein analytical tools. Prior to that, he he

    11/1/23 8:05:00 AM ET
    $NAUT
    Biotechnology: Laboratory Analytical Instruments
    Industrials